



HOP(A) Springs Eternal

By Bryna Delman Ewachiw, PharmD, BCOP
Mark L. Zangardi, PharmD, BCOP

Dr Ewachiw is Abstract Review Subcommittee Chair, 2021-2022, HOPA, and Oncology Pharmacy Coordinator, Sidney Kimmel Cancer Center, Johns Hopkins Bayview Medical Center, Baltimore, MD; Dr Zangardi is Abstract Review Subcommittee Vice Chair, 2021-2022, HOPA, and Pharmacy Coordinator, Oncology Precision Medicine, OhioHealth Pharmacy Services, Columbus, OH.

It is our pleasure to welcome you to this special issue of the *Journal of Hematology Oncology Pharmacy* (JHOP), the official publisher of the Hematology Oncology Pharmacy Association (HOPA). This special issue is the Second Annual Issue of HOPA Abstracts, 2022, highlighting the best and brightest our profession has to offer in oncology research, education, and patient care. The abstracts published here feature the abstracts presented at the 18th HOPA Annual Conference, March 30 through April 2, 2022, in Boston, MA.

The abstracts published in this issue demonstrate the high-quality work submitted by HOPA members and nonmembers, including hematology oncology pharmacists, other healthcare providers, and scientists from across the country and around the world.

The Annual Conference Abstract Review Subcommittee of HOPA has the distinct honor of reviewing completed, late-breaking, and trainee research in clinical/translational research, as well as practice management research. During the submission process, authors can select from a long list of topics, such as benign or malignant hematology, solid tumors, bone marrow transplant, supportive care, medication safety, quality improvement, and the value of cancer care, to name a few.

The Annual Conference Abstract Review Subcommittee is charged with establishing abstract submission criteria, reviewing abstract submissions for unique, innovative content, selecting platform presentations, and judging the Top 10 Trainee poster submissions.

More than 300 completed and late-breaking research abstracts were submitted for consideration this year, all of which were peer reviewed by a committee of subject matter experts from a wide variety of practice areas across the country. Each abstract has been initially carefully reviewed and scored by content experts within the Abstract Review Subcommittee, followed by a discussion of the full committee about the scientific merit and meaningful application of the abstract to HOPA members and to attendees of the HOPA Annual Conference.

Late-breaking research must meet additional criteria to demonstrate a significant impact to oncology pharmacy practice that warrants more immediate review and dissemination. Platform presentations are selected among completed and late-breaking research abstracts, to highlight exceptional research submitted by HOPA members.

The abstracts included in this issue reflect HOPA's mission in educating and supporting hematology oncology pharmacists to be an integral part of cancer care teams.

This year's platform presentations feature research on the impact of providing remote clinical pharmacy services, new approaches in managing neutropenic fever, improving outcomes with a pharmacist-led oral chemotherapy program, and a safety review on sequencing chemotherapy in patients with gastrointestinal malignancies.

In addition, the Annual Conference Abstract Review Subcommittee collaborates with the Annual Conference and Quality and Safety Committee members to provide conference attendees and HOPA members with meaningful and informative content aimed at providing quality and evidence-based patient care.

Today more than ever, hematology oncology pharmacists, pharmacy administrators, and technicians continue to demonstrate their commitment to optimizing the care we provide to individuals who are affected by cancer, by increasing access to treatments, lowering costs, and improving patient safety. The abstracts included in this issue reflect HOPA's mission in educating and supporting hematology oncology pharmacists to be an integral part of cancer care teams, and to improve the quality of care that patients with cancer receive.